Lonza Group AG (LON:0QNO)
London
· Delayed Price · Currency is GBP · Price in CHF 547.69
-2.57 (-0.47%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Integrated Biologics Revenue | 3.78B | 3.68B |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Synthesis Revenue | 1.26B | 983.00M |
Log In |
Log In |
Log In | Upgrade
|
| Specialized Modalities Revenue | 832.00M | 689.00M |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients Revenue | 1.04B | 1.05B |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Revenue | 186.00M | 172.00M |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2019 |
| Europe Revenue | 3.14B |
Log In |
Log In |
Log In | Upgrade
|
| North and Central America Revenue | 2.44B |
Log In |
Log In |
Log In | Upgrade
|
| Latin America Revenue | 129.00M |
Log In |
Log In |
Log In | Upgrade
|
| Asia Revenue | 837.00M |
Log In |
Log In |
Log In | Upgrade
|
| Australia & New Zealand Revenue | 17.00M |
Log In |
Log In |
Log In | Upgrade
|
| Other Geographic Revenue | 3.00M |
Log In |
Log In |
Log In | Upgrade
|
Adjusted EBITDA
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 |
| Integrated Biologics Core EBITDA | 1.33B | 1.27B |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Synthesis Core EBITDA | 489.00M | 351.00M |
Log In |
Log In |
Log In | Upgrade
|
| Specialized Modalities Core EBITDA | 128.00M | 108.00M |
Log In |
Log In |
Log In | Upgrade
|
| Capsules & Health Ingredients Core EBITDA | 259.00M | 256.00M |
Log In |
Log In |
Log In | Upgrade
|
| Corporate Core EBITDA | -127.00M | -73.00M |
Log In |
Log In |
Log In | Upgrade
|